Bristol Myers Squibb is adding a second DGX SuperPOD built on eight DGX Vera Rubin NVL72 systems. The move turns AI infrastructure from a specialist resource into a shared platform for researchers across the company’s global drug-discovery pipeline.
Anthropic is not only selling Claude Science as a research workbench. It says it wants to discover treatments for neglected diseases, raising a harder question: can a frontier AI lab become both a pharma software vendor and a drug developer?
The deal is worth up to about $600M, with roughly $60M in initiation fees, near-term payments, and milestones. Insilico will use Pharma.AI for early discovery while Takeda takes selected candidates into clinical validation and global development.
OpenAI is presenting a more concrete test for AI-assisted science: a chemistry project that reached a validated experimental result. The tweet says GPT-5.4 worked with Molecule.one’s Maria AI and a specialized lab on a drug-discovery reaction.
Life-science AI is moving from literature help toward executable research workflows. OpenAI says GPT-Rosalind reached 27.5% on MedChemBench, 21.6% on GeneBench, and 63.2% on LabWorkBench.
Isomorphic Labs, the AI drug discovery company founded by DeepMind's Demis Hassabis, has raised $2.1 billion in Series B funding led by Thrive Capital. The round includes Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
UCLA researchers have identified DDL-920, the first drug to fully reproduce the effects of physical stroke rehabilitation in model mice. The findings, published in Nature Communications, could transform stroke recovery into a pharmacological option.
IBM Research has published MAMMAL, a multi-modal model that unifies proteins, molecules, and gene data. It achieves state-of-the-art results on 9 of 11 biological benchmarks and outperforms AlphaFold 3 on several drug-discovery tasks.
OpenAI put GPT-Rosalind into research preview for qualified life-science teams, pairing a domain model with a Codex plugin that connects to more than 50 tools and data sources. The strongest signal is not the branding: OpenAI says best-of-ten submissions ranked above the 95th percentile of human experts on one Dyno Therapeutics RNA prediction task.
Roche says it is deploying more than 3,500 NVIDIA Blackwell GPUs across hybrid cloud and on-premises sites in the U.S. and Europe. The company says the new AI factory backbone will support biological foundation models, faster drug discovery, digital twins for manufacturing, and broader AI use across diagnostics and digital health.
NVIDIA says Lilly has brought LillyPod online, a pharma-owned AI factory built with 1,016 Blackwell Ultra GPUs and more than 9,000 petaflops of AI performance. The platform is intended to accelerate model training and simulation across genomics, small molecules, and clinical-development workflows.
Isomorphic Labs, the DeepMind spin-off focused on AI-driven drug discovery, has unveiled a new AI that scientists are calling a generational leap comparable to AlphaFold.